PMID- 33739224
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220531
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 51
IP  - 3
DP  - 2022 Apr
TI  - Association between Interleukin-1beta Polymorphism at Rs16944 and Glucose 
      Metabolism: A Cohort Study.
PG  - 619-629
LID - 10.1080/08820139.2020.1860085 [doi]
AB  - BACKGROUND: This study explored the correlation between the interleukin-1beta gene 
      rs16944 polymorphism and diabetes through epidemiological and follow-up 
      investigations. METHODS: The study was conducted on 600 subjects with normal 
      glucose metabolism recruited from participants of the Risk Evaluation of cAncers 
      in Chinese type 2 diabeTic Individuals: A lONgitudinal (REACTION) study in 
      Luzhou, China in 2011. All subjects received a unified standardized 
      questionnaire, physical examination, laboratory examination, and follow-up in 
      2016. Subjects were divided into normal glucose metabolism (NC), pre-diabetes 
      (PDM), and type 2 diabetes mellitus (T2DM) groups according to their glucose 
      metabolism after follow-up. The IL-1beta gene rs16944 polymorphism was analyzed 
      using the polymerase chain reaction-restriction fragment length 
      polymorphism(PCR-RFLP) technique. RESULTS: After follow-up, 386, 156, and 58 
      cases were observed in the NC, PDM, and T2DM groups, respectively. Serum IL-1beta 
      levels were compared to baselines at follow-up in the 3 groups; the difference in 
      the T2DM group was statistically significant. The frequency distributions of the 
      IL-1beta gene rs16944 genotypes, i.e., CC, CT, and TT, were significantly different 
      in the 3 groups, and the distributions in the T2DM and NC groups were 
      significantly different. The frequency distributions of the C and T alleles of 
      IL-1beta rs16944 were not significantly different. Logistic regression analysis 
      identified the CC+CT genotype as an independent risk factor for the development 
      of diabetes in patients with normal glucose metabolism (OR = 2.457, 95% CI: 
      1.238-4.877). CONCLUSIONS: The IL-1beta gene rs16944 C/T polymorphism may cause 
      genetic susceptibility to T2DM in the Luzhou population. The CC+CT genotypes may 
      increase T2DM risk.
FAU - Cheng, Xiaoling
AU  - Cheng X
AD  - Department of Endocrinology, Luohu People's Hospital, Shenzhen, China.
AD  - Department of Endocrinology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, China.
FAU - Liu, Yiying
AU  - Liu Y
AD  - Department of Endocrinology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, China.
AD  - Key Laboratory of Cardiovascular and Metabolism of LuZhou City, LuZhou, China.
AD  - SiChuan Clinical Research Center for Nephropathy, LuZhou, China.
FAU - Lin, Nengbo
AU  - Lin N
AD  - Department of Endocrinology, Luzhou People's Hospital, LuZhou, China.
FAU - Deng, Sijie
AU  - Deng S
AD  - Department of Endocrinology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, China.
AD  - Key Laboratory of Cardiovascular and Metabolism of LuZhou City, LuZhou, China.
AD  - SiChuan Clinical Research Center for Nephropathy, LuZhou, China.
FAU - Wan, Qin
AU  - Wan Q
AD  - Department of Endocrinology, The Affiliated Hospital of Southwest Medical 
      University, Luzhou, China.
AD  - Key Laboratory of Cardiovascular and Metabolism of LuZhou City, LuZhou, China.
AD  - SiChuan Clinical Research Center for Nephropathy, LuZhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210319
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (IL1B protein, human)
RN  - 0 (Interleukin-1beta)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/genetics
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Glucose
MH  - Humans
MH  - Interleukin-1beta/genetics
MH  - Polymorphism, Single Nucleotide
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - allele frequency
OT  - cohort study
OT  - interleukin-1beta
OT  - risk factors
EDAT- 2021/03/20 06:00
MHDA- 2022/04/06 06:00
CRDT- 2021/03/19 12:17
PHST- 2021/03/20 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2021/03/19 12:17 [entrez]
AID - 10.1080/08820139.2020.1860085 [doi]
PST - ppublish
SO  - Immunol Invest. 2022 Apr;51(3):619-629. doi: 10.1080/08820139.2020.1860085. Epub 
      2021 Mar 19.